Business Wire

OpenOcean–IQM-Lakestar State of Quantum 2022: 63% of Business Leaders Believe Commercialised Quantum Computing to Hit the Market in Five Years

16.11.2022 13:32:00 EET | Business Wire | Press release

Share

Today, OpenOcean, a leading European venture capital firm, IQM Quantum Computers, a European leader in quantum computers, and Lakestar, the leading European technology investor, have released the OpenOcean–IQM-Lakestar State of Quantum 2022 Report, in association with The Quantum Insider (TQI). The report shows that 91% of business leaders are investing or planning to invest in quantum computing, a field in which private investment has grown 500% from a total of $0.4 billion in 2017 to $2.2 billion in 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116005481/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

OpenOcean–IQM-Lakestar State of Quantum 2022 Report (Graphic: Business Wire)

This whitepaper is based on a new online, cross industry survey about quantum readiness along with investment data from TQI and other data sources, collating responses from business leaders across the world to understand their preparation and readiness for commercialised quantum computing.

The findings of this report indicate the means through which investors and decision-makers can bridge the gap between the speed and direction of quantum development and what customers are ready and planning for – tapping into the value created by commercial use cases.

Key findings:

  • 70% of business leaders are using and developing real-life use cases for quantum computing.
  • 61% of business leaders are planning to invest $1 million or more in quantum computing over the next 3 years.
  • 63% of business leaders believe that commercialised quantum computing will hit the market in 5 years.
  • 76% of business leaders agreed that there is a skills crisis in quantum computing: slowing innovation and needing to be addressed as a priority.
  • 61% of business leaders said the hardware costs of running quantum computing are currently not sustainable.
  • Only 10% of firms are cautious that quantum computing will ever be functional for everyday usage.

Preparing for the quantum era

Understanding where the industry currently stands is a critical step for those who wish to take advantage of everything quantum computing has to offer. Investor and customer appetite for real-world use cases and generic, error-correcting quantum machines is growing fast.

Despite challenges arising around the shortage of quantum talent and hardware costs, a significant percentage (33%) of firms see at least an application-specific future for the technology. These businesses understand that quantum computing will bring immense challenges and change over the next few years, identifying the three sectors prime for transformation as cybersecurity; finance; and healthcare, including drug discovery and pharmaceutical research.

Ekaterina Almasque, General Partner at OpenOcean, said: “Our research confirms that we are on a one-way journey to enter the quantum era. The findings are a clear sign that the broader market is starting to buy into the potential of quantum computing, recognising its emerging commercial potential and backing it with significant investment. There is a unique opportunity now for first-movers and businesses to carve out an impactful strategy to operate in the new quantum realm. It was encouraging to see software development as a priority for investment - this is where we also see the dire need for advancements.

“Our mission as an early stage investor in frontier technologies, is to support emerging European leaders in the quantum computing space. These technologies are already hitting the market, and will expand and advance in the decades ahead. The industry is searching for sound investment strategies and concrete examples of added value; this is why we need to be looking for practical solutions. For businesses to make their mark in a competitive landscape, they will need full stack quantum solutions – built and designed for the problems which need most solving.”

Dr. Jan Goetz, CEO and Co-founder of IQM Quantum Computers, said: “I am pleased to see from this report that business leaders in Europe, APAC, and North America are already using quantum computing and are planning significant R&D investments in the near future. With quantum technologies, we can expect several use cases like improvements in drug discovery, encryption and data protection, prediction of financial systems and solutions to other problems. We’ll see significant transformation in industries by bringing together hardware and software, developing application-specific capabilities, and addressing most pressing problems.

“At IQM, we have developed an on-premises strategy to partner with HPC centers and businesses, and this report marks the continuation of our commitment to work with businesses and create a fastlane to quantum advantage.”

Stephen Nundy, Partner & CTO at Lakestar, said: “We fundamentally believe that in order for quantum to reach its full potential in both the short and long term, we must encourage investment and experimentation in quantum software to allow early adoption that feels naturally accretive to existing platforms and technology developed already.

“Customers do not, and should not, need to be quantum-savvy to be able to develop and deploy hybrid quantum applications which solve real-world problems, create business advantages, and harness the best native quantum hardware available. There is certainly much to be excited about in this new computer paradigm - the opportunity for quantum software and hardware companies to work together to build viable platforms for commercial and societal use is already upon us.”

Read the OpenOcean-IQM-Lakestar State of Quantum 2022 Whitepaper here: State of Quantum 2022 Report

About OpenOcean

OpenOcean is an early-stage venture capital firm investing across Europe with offices in London and Helsinki. With an entrepreneurial background from building several category-defining software businesses, we engage with founders to build and scale global companies delivering data solutions for the new economy. OpenOcean typically leads or co-leads Series A funding rounds.

About IQM Quantum Computers

IQM is the pan-European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique application-specific, co-design approach. IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is also building a quantum computer in Germany. This computer will be integrated into an HPC supercomputer to create a quantum accelerator for future scientific research. IQM has over 200 employees with offices in Paris, Madrid, Munich, and Espoo.

About Lakestar

Lakestar’s mission is to find, fund and grow disruptive businesses - enabled by technology - that are founded by exceptional entrepreneurs in Europe and beyond. Founded by Klaus Hommels, the team’s early investments include Skype, Spotify, Facebook and Airbnb. Since raising its first fund in 2012, Lakestar manages an aggregated volume of over €1.2bn across three early stage funds and a growth fund.

The team actively advises and supports portfolio companies in marketing, recruitment, technology, product development and regulatory insight, accompanying founders from seed to early stage to growth stage or exit. Lakestar currently has the privilege of holding investments in Revolut, Blockchain.com, Opendoor, Oscar, GetYourGuide, sennder, Eigen, Public.com, SoFi, Solarisbank, Uncapped, Yapily, Terra Quantum, accuRx, Rhino, ZEBEDEE and Hometogo to name a few. Lakestar has presence in Berlin, Zurich and London.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

IQM Media Contact
Raghunath Koduvayur, Head of Marketing and Communications
Email: Raghunath@meetiqm.com
Mobile: +358 50 4876509
www.meetiqm.com

OpenOcean Media Contact
Alex Izza, Account Director
Email: alex@resonancecrowd.com
Mobile: +44 (0) 759 189 9654
www.openocean.vc

Lakestar Media Contact
Tom Climie
Email: tom.climie@kekstcnc.com
Tel.: +44 7760 160 248

Marisa Wagner
Email: marisa.wagner@kekstcnc.com
Tel: +49 152 543 727 77
www.lakestar.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye